Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
11
BDTX Quote, Financials, Valuation and Earnings
Last price:
$2.59
Seasonality move
:
-28.39%
Day range:
$2.54 - $2.66
52-week range:
$1.20 - $4.94
Dividend yield:
0%
P/E ratio:
7.14x
P/S ratio:
2.11x
P/B ratio:
1.17x
Volume:
838.6K
Avg. volume:
1.5M
1-year change:
12.61%
Market cap:
$147.6M
Revenue:
--
EPS (TTM):
$0.36
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BDTX
Black Diamond Therapeutics, Inc.
|
$10.7M | $0.06 | -100% | -39.8% | $9.25 |
|
ABOS
Acumen Pharmaceuticals, Inc.
|
-- | -$0.46 | -- | -10.03% | $6.40 |
|
EBS
Emergent BioSolutions, Inc.
|
$275M | -$0.12 | 11.71% | -94.67% | $13.50 |
|
JNJ
Johnson & Johnson
|
$23.1B | $2.75 | 7.18% | 79.14% | $209.29 |
|
ORIC
Oric Pharmaceuticals, Inc.
|
-- | -$0.38 | -- | -28.72% | $20.92 |
|
PBYI
Puma Biotechnology, Inc.
|
$49M | $0.04 | 16.12% | -41.13% | $3.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BDTX
Black Diamond Therapeutics, Inc.
|
$2.59 | $9.25 | $147.6M | 7.14x | $0.00 | 0% | 2.11x |
|
ABOS
Acumen Pharmaceuticals, Inc.
|
$2.11 | $6.40 | $127.8M | -- | $0.00 | 0% | -- |
|
EBS
Emergent BioSolutions, Inc.
|
$12.43 | $13.50 | $652.8M | 9.61x | $0.00 | 0% | 0.88x |
|
JNJ
Johnson & Johnson
|
$207.63 | $209.29 | $500.2B | 20.04x | $1.30 | 2.48% | 5.46x |
|
ORIC
Oric Pharmaceuticals, Inc.
|
$8.25 | $20.92 | $803.5M | -- | $0.00 | 0% | -- |
|
PBYI
Puma Biotechnology, Inc.
|
$6.16 | $3.50 | $310.4M | 8.32x | $0.00 | 0% | 1.46x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BDTX
Black Diamond Therapeutics, Inc.
|
13.49% | 4.929 | 9.11% | 8.72x |
|
ABOS
Acumen Pharmaceuticals, Inc.
|
24.87% | 2.669 | 29.77% | 5.77x |
|
EBS
Emergent BioSolutions, Inc.
|
53.53% | 4.454 | 144.36% | 2.93x |
|
JNJ
Johnson & Johnson
|
36.62% | 0.235 | 10.26% | 0.71x |
|
ORIC
Oric Pharmaceuticals, Inc.
|
0.81% | 6.100 | 0.28% | 14.23x |
|
PBYI
Puma Biotechnology, Inc.
|
26.26% | 1.268 | 15.34% | 1.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BDTX
Black Diamond Therapeutics, Inc.
|
-$86K | -$11M | 15.62% | 18.5% | 77.9% | -$7.9M |
|
ABOS
Acumen Pharmaceuticals, Inc.
|
-$47K | -$26.5M | -72.85% | -87.18% | -- | -$30.5M |
|
EBS
Emergent BioSolutions, Inc.
|
$129.1M | $76.8M | 6.29% | 14.25% | 33.23% | -$5.7M |
|
JNJ
Johnson & Johnson
|
$16.7B | $7.1B | 20.94% | 33.27% | 29.64% | $8B |
|
ORIC
Oric Pharmaceuticals, Inc.
|
-$288K | -$36.7M | -45.39% | -46.08% | -- | -$26.9M |
|
PBYI
Puma Biotechnology, Inc.
|
$42.3M | $9.6M | 23.32% | 38.49% | 17.57% | $9.7M |
Black Diamond Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns BDTX or ABOS?
Acumen Pharmaceuticals, Inc. has a net margin of 80.77% compared to Black Diamond Therapeutics, Inc.'s net margin of --. Black Diamond Therapeutics, Inc.'s return on equity of 18.5% beat Acumen Pharmaceuticals, Inc.'s return on equity of -87.18%.
Company Gross Margin Earnings Per Share Invested Capital BDTXBlack Diamond Therapeutics, Inc.-- -$0.15 $145.8M ABOSAcumen Pharmaceuticals, Inc.-- -$0.44 $124M -
What do Analysts Say About BDTX or ABOS?
Black Diamond Therapeutics, Inc. has a consensus price target of $9.25, signalling upside risk potential of 264.04%. On the other hand Acumen Pharmaceuticals, Inc. has an analysts' consensus of $6.40 which suggests that it could grow by 203.32%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than Acumen Pharmaceuticals, Inc., analysts believe Black Diamond Therapeutics, Inc. is more attractive than Acumen Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BDTXBlack Diamond Therapeutics, Inc.6 1 0 ABOSAcumen Pharmaceuticals, Inc.6 0 0 -
Is BDTX or ABOS More Risky?
Black Diamond Therapeutics, Inc. has a beta of 3.331, which suggesting that the stock is 233.083% more volatile than S&P 500. In comparison Acumen Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BDTX or ABOS?
Black Diamond Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Acumen Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics, Inc. pays -- of its earnings as a dividend. Acumen Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDTX or ABOS?
Black Diamond Therapeutics, Inc. quarterly revenues are --, which are smaller than Acumen Pharmaceuticals, Inc. quarterly revenues of --. Black Diamond Therapeutics, Inc.'s net income of -$8.5M is higher than Acumen Pharmaceuticals, Inc.'s net income of -$26.5M. Notably, Black Diamond Therapeutics, Inc.'s price-to-earnings ratio is 7.14x while Acumen Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics, Inc. is 2.11x versus -- for Acumen Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDTXBlack Diamond Therapeutics, Inc.2.11x 7.14x -- -$8.5M ABOSAcumen Pharmaceuticals, Inc.-- -- -- -$26.5M
-
Which has Higher Returns BDTX or EBS?
Emergent BioSolutions, Inc. has a net margin of 80.77% compared to Black Diamond Therapeutics, Inc.'s net margin of 22.16%. Black Diamond Therapeutics, Inc.'s return on equity of 18.5% beat Emergent BioSolutions, Inc.'s return on equity of 14.25%.
Company Gross Margin Earnings Per Share Invested Capital BDTXBlack Diamond Therapeutics, Inc.-- -$0.15 $145.8M EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B -
What do Analysts Say About BDTX or EBS?
Black Diamond Therapeutics, Inc. has a consensus price target of $9.25, signalling upside risk potential of 264.04%. On the other hand Emergent BioSolutions, Inc. has an analysts' consensus of $13.50 which suggests that it could grow by 8.61%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Black Diamond Therapeutics, Inc. is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BDTXBlack Diamond Therapeutics, Inc.6 1 0 EBSEmergent BioSolutions, Inc.2 0 0 -
Is BDTX or EBS More Risky?
Black Diamond Therapeutics, Inc. has a beta of 3.331, which suggesting that the stock is 233.083% more volatile than S&P 500. In comparison Emergent BioSolutions, Inc. has a beta of 2.318, suggesting its more volatile than the S&P 500 by 131.831%.
-
Which is a Better Dividend Stock BDTX or EBS?
Black Diamond Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Emergent BioSolutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics, Inc. pays -- of its earnings as a dividend. Emergent BioSolutions, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDTX or EBS?
Black Diamond Therapeutics, Inc. quarterly revenues are --, which are smaller than Emergent BioSolutions, Inc. quarterly revenues of $231.1M. Black Diamond Therapeutics, Inc.'s net income of -$8.5M is lower than Emergent BioSolutions, Inc.'s net income of $51.2M. Notably, Black Diamond Therapeutics, Inc.'s price-to-earnings ratio is 7.14x while Emergent BioSolutions, Inc.'s PE ratio is 9.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics, Inc. is 2.11x versus 0.88x for Emergent BioSolutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDTXBlack Diamond Therapeutics, Inc.2.11x 7.14x -- -$8.5M EBSEmergent BioSolutions, Inc.0.88x 9.61x $231.1M $51.2M
-
Which has Higher Returns BDTX or JNJ?
Johnson & Johnson has a net margin of 80.77% compared to Black Diamond Therapeutics, Inc.'s net margin of 21.47%. Black Diamond Therapeutics, Inc.'s return on equity of 18.5% beat Johnson & Johnson's return on equity of 33.27%.
Company Gross Margin Earnings Per Share Invested Capital BDTXBlack Diamond Therapeutics, Inc.-- -$0.15 $145.8M JNJJohnson & Johnson69.72% $2.12 $125.1B -
What do Analysts Say About BDTX or JNJ?
Black Diamond Therapeutics, Inc. has a consensus price target of $9.25, signalling upside risk potential of 264.04%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 0.8%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Black Diamond Therapeutics, Inc. is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings BDTXBlack Diamond Therapeutics, Inc.6 1 0 JNJJohnson & Johnson9 11 0 -
Is BDTX or JNJ More Risky?
Black Diamond Therapeutics, Inc. has a beta of 3.331, which suggesting that the stock is 233.083% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.
-
Which is a Better Dividend Stock BDTX or JNJ?
Black Diamond Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.48% to investors and pays a quarterly dividend of $1.30 per share. Black Diamond Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDTX or JNJ?
Black Diamond Therapeutics, Inc. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24B. Black Diamond Therapeutics, Inc.'s net income of -$8.5M is lower than Johnson & Johnson's net income of $5.2B. Notably, Black Diamond Therapeutics, Inc.'s price-to-earnings ratio is 7.14x while Johnson & Johnson's PE ratio is 20.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics, Inc. is 2.11x versus 5.46x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDTXBlack Diamond Therapeutics, Inc.2.11x 7.14x -- -$8.5M JNJJohnson & Johnson5.46x 20.04x $24B $5.2B
-
Which has Higher Returns BDTX or ORIC?
Oric Pharmaceuticals, Inc. has a net margin of 80.77% compared to Black Diamond Therapeutics, Inc.'s net margin of --. Black Diamond Therapeutics, Inc.'s return on equity of 18.5% beat Oric Pharmaceuticals, Inc.'s return on equity of -46.08%.
Company Gross Margin Earnings Per Share Invested Capital BDTXBlack Diamond Therapeutics, Inc.-- -$0.15 $145.8M ORICOric Pharmaceuticals, Inc.-- -$0.33 $410.2M -
What do Analysts Say About BDTX or ORIC?
Black Diamond Therapeutics, Inc. has a consensus price target of $9.25, signalling upside risk potential of 264.04%. On the other hand Oric Pharmaceuticals, Inc. has an analysts' consensus of $20.92 which suggests that it could grow by 153.54%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than Oric Pharmaceuticals, Inc., analysts believe Black Diamond Therapeutics, Inc. is more attractive than Oric Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BDTXBlack Diamond Therapeutics, Inc.6 1 0 ORICOric Pharmaceuticals, Inc.12 1 0 -
Is BDTX or ORIC More Risky?
Black Diamond Therapeutics, Inc. has a beta of 3.331, which suggesting that the stock is 233.083% more volatile than S&P 500. In comparison Oric Pharmaceuticals, Inc. has a beta of 1.324, suggesting its more volatile than the S&P 500 by 32.373%.
-
Which is a Better Dividend Stock BDTX or ORIC?
Black Diamond Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oric Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics, Inc. pays -- of its earnings as a dividend. Oric Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDTX or ORIC?
Black Diamond Therapeutics, Inc. quarterly revenues are --, which are smaller than Oric Pharmaceuticals, Inc. quarterly revenues of --. Black Diamond Therapeutics, Inc.'s net income of -$8.5M is higher than Oric Pharmaceuticals, Inc.'s net income of -$32.6M. Notably, Black Diamond Therapeutics, Inc.'s price-to-earnings ratio is 7.14x while Oric Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics, Inc. is 2.11x versus -- for Oric Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDTXBlack Diamond Therapeutics, Inc.2.11x 7.14x -- -$8.5M ORICOric Pharmaceuticals, Inc.-- -- -- -$32.6M
-
Which has Higher Returns BDTX or PBYI?
Puma Biotechnology, Inc. has a net margin of 80.77% compared to Black Diamond Therapeutics, Inc.'s net margin of 16.24%. Black Diamond Therapeutics, Inc.'s return on equity of 18.5% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.
Company Gross Margin Earnings Per Share Invested Capital BDTXBlack Diamond Therapeutics, Inc.-- -$0.15 $145.8M PBYIPuma Biotechnology, Inc.77.65% $0.17 $156.3M -
What do Analysts Say About BDTX or PBYI?
Black Diamond Therapeutics, Inc. has a consensus price target of $9.25, signalling upside risk potential of 264.04%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -43.18%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Black Diamond Therapeutics, Inc. is more attractive than Puma Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BDTXBlack Diamond Therapeutics, Inc.6 1 0 PBYIPuma Biotechnology, Inc.0 1 0 -
Is BDTX or PBYI More Risky?
Black Diamond Therapeutics, Inc. has a beta of 3.331, which suggesting that the stock is 233.083% more volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.656%.
-
Which is a Better Dividend Stock BDTX or PBYI?
Black Diamond Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDTX or PBYI?
Black Diamond Therapeutics, Inc. quarterly revenues are --, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Black Diamond Therapeutics, Inc.'s net income of -$8.5M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Black Diamond Therapeutics, Inc.'s price-to-earnings ratio is 7.14x while Puma Biotechnology, Inc.'s PE ratio is 8.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics, Inc. is 2.11x versus 1.46x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDTXBlack Diamond Therapeutics, Inc.2.11x 7.14x -- -$8.5M PBYIPuma Biotechnology, Inc.1.46x 8.32x $54.5M $8.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
